Amylyx Pharmaceuticals IncNASDAQ:AMLX
- LAST PRICE3.0800
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots2.9400/ 8
- Ask / Lots3.1400/ 15
- Open / Previous Close--- / 3.0800
- Day Range---
- 52 Week Range
- Volume120
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | AMLX |
|---|---|---|
| 09:32 ET | 16937 | 3.15 |
| 09:34 ET | 5806 | 3.1291 |
| 09:36 ET | 1875 | 3.12 |
| 09:38 ET | 6959 | 3.13 |
| 09:39 ET | 300 | 3.12 |
| 09:41 ET | 12200 | 3.0923 |
| 09:43 ET | 400 | 3.08 |
| 09:45 ET | 2230 | 3.08 |
| 09:48 ET | 1176 | 3.07 |
| 09:50 ET | 5192 | 3.06 |
| 09:52 ET | 1868 | 3.07 |
| 09:56 ET | 5500 | 3.05 |
| 09:57 ET | 400 | 3.05 |
| 09:59 ET | 1322 | 3.06 |
| 10:03 ET | 281 | 3.065 |
| 10:06 ET | 889 | 3.06 |
| 10:08 ET | 38455 | 3.1 |
| 10:10 ET | 200 | 3.09 |
| 10:12 ET | 200 | 3.085 |
| 10:14 ET | 200 | 3.085 |
| 10:17 ET | 1267 | 3.085 |
| 10:19 ET | 300 | 3.085 |
| 10:21 ET | 411 | 3.085 |
| 10:24 ET | 2350 | 3.075 |
| 10:26 ET | 7107 | 3.095 |
| 10:28 ET | 2028 | 3.095 |
| 10:30 ET | 467 | 3.09 |
| 10:32 ET | 2964 | 3.085 |
| 10:33 ET | 1688 | 3.075 |
| 10:35 ET | 2131 | 3.095 |
| 10:42 ET | 11960 | 3.1 |
| 10:46 ET | 3466 | 3.095 |
| 10:51 ET | 100 | 3.095 |
| 10:55 ET | 710 | 3.095 |
| 10:57 ET | 2000 | 3.0917 |
| 11:00 ET | 2500 | 3.095 |
| 11:02 ET | 1711 | 3.09 |
| 11:04 ET | 864 | 3.08 |
| 11:06 ET | 400 | 3.075 |
| 11:08 ET | 3566 | 3.08 |
| 11:09 ET | 4039 | 3.075 |
| 11:11 ET | 100 | 3.075 |
| 11:13 ET | 177 | 3.08 |
| 11:15 ET | 985 | 3.085 |
| 11:18 ET | 1000 | 3.085 |
| 11:20 ET | 790 | 3.08 |
| 11:22 ET | 950 | 3.1 |
| 11:24 ET | 400 | 3.085 |
| 11:26 ET | 200 | 3.085 |
| 11:27 ET | 300 | 3.08 |
| 11:29 ET | 400 | 3.085 |
| 11:31 ET | 300 | 3.085 |
| 11:33 ET | 100 | 3.085 |
| 11:36 ET | 1864 | 3.085 |
| 11:38 ET | 6584 | 3.105 |
| 11:40 ET | 1211 | 3.1 |
| 11:44 ET | 531 | 3.098 |
| 11:45 ET | 1580 | 3.095 |
| 11:47 ET | 800 | 3.09 |
| 11:49 ET | 6778 | 3.075 |
| 11:51 ET | 500 | 3.075 |
| 11:54 ET | 600 | 3.075 |
| 11:56 ET | 100 | 3.075 |
| 11:58 ET | 400 | 3.075 |
| 12:00 ET | 1100 | 3.075 |
| 12:03 ET | 3632 | 3.075 |
| 12:05 ET | 700 | 3.075 |
| 12:07 ET | 300 | 3.075 |
| 12:09 ET | 100 | 3.075 |
| 12:12 ET | 1764 | 3.07 |
| 12:14 ET | 500 | 3.06 |
| 12:16 ET | 2207 | 3.065 |
| 12:18 ET | 1848 | 3.065 |
| 12:20 ET | 819 | 3.065 |
| 12:21 ET | 190 | 3.07 |
| 12:27 ET | 100 | 3.065 |
| 12:30 ET | 200 | 3.065 |
| 12:32 ET | 100 | 3.065 |
| 12:34 ET | 295 | 3.06 |
| 12:36 ET | 5911 | 3.065 |
| 12:38 ET | 365 | 3.065 |
| 12:43 ET | 326 | 3.065 |
| 12:48 ET | 1600 | 3.06 |
| 12:50 ET | 650 | 3.06 |
| 12:52 ET | 500 | 3.055 |
| 12:56 ET | 2192 | 3.06 |
| 12:57 ET | 327 | 3.0609 |
| 12:59 ET | 800 | 3.055 |
| 01:03 ET | 4600 | 3.055 |
| 01:06 ET | 2109 | 3.055 |
| 01:08 ET | 2340 | 3.055 |
| 01:10 ET | 100 | 3.055 |
| 01:12 ET | 5444 | 3.06 |
| 01:15 ET | 237 | 3.055 |
| 01:17 ET | 2851 | 3.055 |
| 01:19 ET | 962 | 3.055 |
| 01:21 ET | 2300 | 3.055 |
| 01:24 ET | 1750 | 3.055 |
| 01:26 ET | 7729 | 3.055 |
| 01:28 ET | 200 | 3.055 |
| 01:30 ET | 1500 | 3.055 |
| 01:32 ET | 1000 | 3.055 |
| 01:33 ET | 546 | 3.055 |
| 01:35 ET | 4800 | 3.055 |
| 01:37 ET | 1288 | 3.055 |
| 01:39 ET | 846 | 3.055 |
| 01:42 ET | 400 | 3.055 |
| 01:44 ET | 2876 | 3.045 |
| 01:46 ET | 2010 | 3.055 |
| 01:48 ET | 200 | 3.05 |
| 01:50 ET | 200 | 3.05 |
| 01:51 ET | 827 | 3.05 |
| 01:53 ET | 3598 | 3.05 |
| 01:57 ET | 4600 | 3.0599 |
| 02:00 ET | 100 | 3.055 |
| 02:06 ET | 3839 | 3.055 |
| 02:08 ET | 1038 | 3.055 |
| 02:09 ET | 1053 | 3.0595 |
| 02:13 ET | 100 | 3.055 |
| 02:15 ET | 2600 | 3.055 |
| 02:20 ET | 7189 | 3.075 |
| 02:22 ET | 726 | 3.07 |
| 02:24 ET | 2895 | 3.07 |
| 02:26 ET | 300 | 3.07 |
| 02:27 ET | 473 | 3.075 |
| 02:29 ET | 731 | 3.075 |
| 02:31 ET | 9041 | 3.075 |
| 02:33 ET | 3587 | 3.065 |
| 02:36 ET | 1441 | 3.065 |
| 02:38 ET | 200 | 3.065 |
| 02:42 ET | 300 | 3.065 |
| 02:44 ET | 1910 | 3.055 |
| 02:47 ET | 5046 | 3.055 |
| 02:49 ET | 7599 | 3.045 |
| 02:51 ET | 2300 | 3.055 |
| 02:54 ET | 9690 | 3.06 |
| 02:56 ET | 2761 | 3.0508 |
| 02:58 ET | 100 | 3.055 |
| 03:02 ET | 7831 | 3.055 |
| 03:03 ET | 305 | 3.055 |
| 03:05 ET | 500 | 3.055 |
| 03:07 ET | 966 | 3.055 |
| 03:09 ET | 200 | 3.06 |
| 03:12 ET | 200 | 3.055 |
| 03:14 ET | 117 | 3.055 |
| 03:16 ET | 150 | 3.06 |
| 03:18 ET | 100 | 3.05 |
| 03:20 ET | 300 | 3.05 |
| 03:21 ET | 4765 | 3.07 |
| 03:23 ET | 1061 | 3.065 |
| 03:27 ET | 1000 | 3.065 |
| 03:30 ET | 1363 | 3.065 |
| 03:32 ET | 1461 | 3.06 |
| 03:34 ET | 4033 | 3.07 |
| 03:36 ET | 201 | 3.0783 |
| 03:38 ET | 4700 | 3.075 |
| 03:39 ET | 203 | 3.075 |
| 03:41 ET | 4777 | 3.085 |
| 03:43 ET | 5085 | 3.0843 |
| 03:45 ET | 439 | 3.085 |
| 03:48 ET | 600 | 3.0837 |
| 03:50 ET | 863 | 3.085 |
| 03:52 ET | 9530 | 3.0791 |
| 03:54 ET | 15671 | 3.085 |
| 03:56 ET | 2939 | 3.0899 |
| 03:57 ET | 21704 | 3.085 |
| 03:59 ET | 312858 | 3.08 |
Oct 3, 2024
Kuehn Law Encourages Investors of Amylyx Pharmaceuticals, Inc. to Contact Law Firm, from 3:06PM ET on Thursday Oct 03, 2024 by Dow Jones
3:06PM ET on Thursday Oct 03, 2024 by Dow Jones
Sep 16, 2024
Kuehn Law Encourages Investors of Amylyx Pharmaceuticals, Inc. to Contact Law Firm, from 11:42AM ET on Monday Sep 16, 2024 by Dow Jones
11:42AM ET on Monday Sep 16, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Amylyx Pharmaceuticals Inc | 209.7M | -1.3x | --- |
Amarin Corporation PLC | 236.7M | -7.0x | --- |
Organogenesis Holdings Inc | 396.4M | -23.9x | --- |
Ironwood Pharmaceuticals Inc | 640.6M | 92.8x | --- |
Sinovac Biotech Ltd | 639.9M | -4.9x | --- |
Coherus BioSciences Inc | 123.3M | -2.7x | --- |
Company Information
Amylyx Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in the discovery and development of treatments for neurodegenerative diseases. The Company is focused on the development and commercialization of its product candidate: AMX0035 for the treatment of Wolfram syndrome and for the treatment of progressive supranuclear palsy, and AMX0114, the Company’s antisense oligonucleotide targeting calpain-2 for the treatment of amyotrophic lateral sclerosis (ALS). AMX0035 is a dual-unfolded protein response (UPR)-Bax apoptosis inhibitor composed of PB and TURSO (also known as TUDCA). The Company’s Avexitide is an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist that has been evaluated in five clinical trials for post-bariatric hypoglycemia (PBH) and has also been studied in congenital hyperinsulinism (HI), two indications characterized by hyperinsulinemic hypoglycemia.
Contact Information
- Headquarters
- 43 THORNDIKE STREETCAMBRIDGE, MA, United States 02141
- Phone
- 617-682-0917
- Fax
- 302-636-5454
Executives
- Chair of the Board of Directors
- George Milne
- Co-Chief Executive Officer, Director
- Joshua Cohen
- Co-Chief Executive Officer, Director
- Justin Klee
- Chief Financial Officer
- James Frates
- Chief Legal Officer and General Counsel
- Gina Mazzariello
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $209.7M |
|---|---|
Revenue (TTM) | $298.8M |
Shares Outstanding | 68.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-2.45 |
Book Value | $6.40 |
P/E Ratio | -1.3x |
Price/Sales (TTM) | 0.7 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -59.50% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
